Selected research
Industry Growth & Trends
Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the ESR1 Mutated Metastatic Breast Cancer Diagnostics market include APIS Assay Technologies, lllumina, Inc., GENCURIX, RainSure Scientific, NeoGenomics Laboratories, Sysmex Corporation, ASURAGEN,INC and Guardant Health, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The ESR1 Mutated Metastatic Breast Cancer Diagnostics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to ESR1 Mutated Metastatic Breast Cancer Diagnostics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Company
APIS Assay Technologies
lllumina, Inc.
GENCURIX
RainSure Scientific
NeoGenomics Laboratories
Sysmex Corporation
ASURAGEN,INC
Guardant Health
ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Type
NGS Based
PCR Based
ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Application
Hospital Associated Labs
lndependent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research lnstitutes
ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of ESR1 Mutated Metastatic Breast Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ESR1 Mutated Metastatic Breast Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of ESR1 Mutated Metastatic Breast Cancer Diagnostics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- NGS Based
- PCR Based
Applications
- Hospital Associated Labs
- lndependent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research lnstitutes
Companies covered
- APIS Assay Technologies
- lllumina, Inc.
- GENCURIX
- RainSure Scientific
- NeoGenomics Laboratories
- Sysmex Corporation
- ASURAGEN,INC
- Guardant Health
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2032)
- 1.4.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026)
- 1.4.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2027-2032)
- 1.5 Key Regions ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2021-2032)
- 1.5.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (2021-2032)
- 1.5.4 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (2021-2032)
2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Type
- 2.1 Type Introduction
- 2.1.1 NGS Based
- 2.1.2 PCR Based
- 2.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type
- 2.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Overview by Type (2021-2032)
- 2.2.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecasted by Type (2027-2032)
- 2.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Regions
- 2.3.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Breakdown by Type (2021-2026)
3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital Associated Labs
- 3.1.2 lndependent Diagnostic Laboratories
- 3.1.3 Diagnostic Imaging Centers
- 3.1.4 Cancer Research lnstitutes
- 3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application
- 3.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Overview by Application (2021-2032)
- 3.2.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecasted by Application (2027-2032)
- 3.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Regions
- 3.3.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Trends
- 4.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Drivers
- 4.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Opportunities and Challenges
- 4.4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (2021-2026)
- 5.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Company Headquarters & Area Served
- 5.4 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company, Product Type & Application
- 5.5 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 ESR1 Mutated Metastatic Breast Cancer Diagnostics Players Market Share by Revenue in 2025
- 5.6.3 2025 ESR1 Mutated Metastatic Breast Cancer Diagnostics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 APIS Assay Technologies
- 6.1.1 APIS Assay Technologies Company Information
- 6.1.2 APIS Assay Technologies Business Overview
- 6.1.3 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
- 6.1.5 APIS Assay Technologies Recent Developments
- 6.2 lllumina, Inc.
- 6.2.1 lllumina, Inc. Company Information
- 6.2.2 lllumina, Inc. Business Overview
- 6.2.3 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
- 6.2.5 lllumina, Inc. Recent Developments
- 6.3 GENCURIX
- 6.3.1 GENCURIX Company Information
- 6.3.2 GENCURIX Business Overview
- 6.3.3 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
- 6.3.5 GENCURIX Recent Developments
- 6.4 RainSure Scientific
- 6.4.1 RainSure Scientific Company Information
- 6.4.2 RainSure Scientific Business Overview
- 6.4.3 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
- 6.4.5 RainSure Scientific Recent Developments
- 6.5 NeoGenomics Laboratories
- 6.5.1 NeoGenomics Laboratories Company Information
- 6.5.2 NeoGenomics Laboratories Business Overview
- 6.5.3 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
- 6.5.5 NeoGenomics Laboratories Recent Developments
- 6.6 Sysmex Corporation
- 6.6.1 Sysmex Corporation Company Information
- 6.6.2 Sysmex Corporation Business Overview
- 6.6.3 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
- 6.6.5 Sysmex Corporation Recent Developments
- 6.7 ASURAGEN,INC
- 6.7.1 ASURAGEN,INC Company Information
- 6.7.2 ASURAGEN,INC Business Overview
- 6.7.3 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
- 6.7.5 ASURAGEN,INC Recent Developments
- 6.8 Guardant Health
- 6.8.1 Guardant Health Company Information
- 6.8.2 Guardant Health Business Overview
- 6.8.3 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
- 6.8.5 Guardant Health Recent Developments
7 North America
- 7.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026)
- 7.3 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026)
- 8.3 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026)
- 10.3 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst